- Home
- IFRX vs CLPR Comparison
IFRX vs CLPR Comparison
Compare IFRX & CLPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- CLPR
- Stock Information
- Founded
- IFRX 2007
- CLPR 2015
- Country
- IFRX Germany
- CLPR United States
- Employees
- IFRX N/A
- CLPR N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- CLPR Real Estate Investment Trusts
- Sector
- IFRX Health Care
- CLPR Real Estate
- Exchange
- IFRX Nasdaq
- CLPR Nasdaq
- Market Cap
- IFRX 65.8M
- CLPR 57.8M
- IPO Year
- IFRX 2017
- CLPR 2017
- Fundamental
- Price
- IFRX $1.69
- CLPR $4.16
- Analyst Decision
- IFRX Strong Buy
- CLPR
- Analyst Count
- IFRX 4
- CLPR 0
- Target Price
- IFRX $8.50
- CLPR N/A
- AVG Volume (30 Days)
- IFRX 262.5K
- CLPR 92.7K
- Earning Date
- IFRX 05-07-2025
- CLPR 05-12-2025
- Dividend Yield
- IFRX N/A
- CLPR 9.11%
- EPS Growth
- IFRX N/A
- CLPR N/A
- EPS
- IFRX N/A
- CLPR N/A
- Revenue
- IFRX $140,242.00
- CLPR $152,413,000.00
- Revenue This Year
- IFRX $61.96
- CLPR N/A
- Revenue Next Year
- IFRX $80.59
- CLPR N/A
- P/E Ratio
- IFRX N/A
- CLPR N/A
- Revenue Growth
- IFRX 30.90
- CLPR 8.63
- 52 Week Low
- IFRX $0.82
- CLPR $3.38
- 52 Week High
- IFRX $2.82
- CLPR $7.12
- Technical
- Relative Strength Index (RSI)
- IFRX 62.40
- CLPR 61.61
- Support Level
- IFRX $1.53
- CLPR $3.95
- Resistance Level
- IFRX $1.92
- CLPR $4.29
- Average True Range (ATR)
- IFRX 0.19
- CLPR 0.17
- MACD
- IFRX 0.02
- CLPR 0.04
- Stochastic Oscillator
- IFRX 74.59
- CLPR 83.95
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.